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Abstract: BACKGROUND Identification of patients at high risk of 
treatment-resistant schizophrenia (TRS) at the time of diagnosing 
schizophrenia would be of great clinical benefit when considering 
clozapine treatment earlier for patients unlikely to respond to non-
clozapine antipsychotics. Knowledge about TRS predictors is limited. 
Using a treatment-based proxy for TRS, we aimed to identify candidate 
predictors of TRS at first hospital contact with a schizophrenia 
diagnosis. 
METHODS Using Danish National registry data we conducted a population-
based cohort study among all adult patients with incident schizophrenia 
between January 1, 1996 and December 31, 2006 followed until 31 December, 
2010. As main TRS proxy definition we considered the earliest instance of 
either (i) clozapine initiation or (ii) hospitalization for schizophrenia 
after having had two periods of different antipsychotic monotherapy. We 
performed multivariable Cox proportional hazards regression analysis.  
FINDINGS Of 8624 patients with schizophrenia, 21·1% fulfilled the TRS 
proxy definition during follow-up (median 9·1 years, IQR: 6·3-11·9). 
Younger age, living in a less urban area, higher education, previous 
psychiatric hospitalization, paranoid subtype, comorbid personality 
disorder, psychotropic drug use, and previous suicide attempt, were all 
significantly associated with an increased rate of TRS. 
INTERPRETATION The current study identifies several candidate predictors 
which could potentially be included in future prediction models for TRS. 
Notably, established risk factors for schizophrenia did not predict TRS, 
suggesting that TRS may be a distinct subtype of schizophrenia, and not 
merely a more severe form of schizophrenia.  
FUNDING The research leading to these results has received funding from 
the European Community's Seventh Framework Programme (FP7/2007-2013) 
under grant agreement n° 279227. The funding agency has had no impact in 
any aspect of data review, interpretation and manuscript writing. 
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Abstract 
BACKGROUND Identification of patients at high risk of treatment-resistant schizophrenia (TRS) at the 
time of diagnosing schizophrenia would be of great clinical benefit when considering clozapine treatment 
earlier for patients unlikely to respond to non-clozapine antipsychotics. Knowledge about TRS predictors 
is limited. Using a treatment-based proxy for TRS, we aimed to identify candidate predictors of TRS at 
first hospital contact with a schizophrenia diagnosis. 
METHODS Using Danish National registry data we conducted a population-based cohort study among 
all adult patients with incident schizophrenia between January 1, 1996 and December 31, 2006 followed 
until 31 December, 2010. As main TRS proxy definition we considered the earliest instance of either (i) 
clozapine initiation or (ii) hospitalization for schizophrenia after having had two periods of different 
antipsychotic monotherapy. We performed multivariable Cox proportional hazards regression analysis.  
FINDINGS Of 8624 patients with schizophrenia, 21·1% fulfilled the TRS proxy definition during 
follow-up (median 9·1 years, IQR: 6·3-11·9). Younger age, living in a less urban area, higher education, 
previous psychiatric hospitalization, paranoid subtype, comorbid personality disorder, psychotropic drug 
use, and previous suicide attempt, were all significantly associated with an increased rate of TRS. 
INTERPRETATION The current study identifies several candidate predictors which could potentially 
be included in future prediction models for TRS. Notably, established risk factors for schizophrenia did 
not predict TRS, suggesting that TRS may be a distinct subtype of schizophrenia, and not merely a more 
severe form of schizophrenia.  
FUNDING The research leading to these results has received funding from the European Community's 
Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 279227. The funding agency 
has had no impact in any aspect of data review, interpretation and manuscript writing. 
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Introduction 
Treatment-resistant schizophrenia (TRS) is clinically defined as non-response to at least two adequate 
trials of antipsychotic medication, and is estimated to affect approximately 30% of all patients with 
schizophrenia.
1 and 2
 
Clozapine is the only treatment for TRS with a firm evidence base as reflected by official treatment 
guidelines
2
. Compared with the estimated prevalence of TRS of 30%, the prevalence of clozapine 
prescription varies from 2-3% in parts of the US
3
, to nearly 60% in China
3 and 4
 with around 10% in most 
Western European countries including Denmark
5
. This is partly a consequence of variations between 
national treatment guidelines.
6 and 7
 Moreover, the low rate of clozapine treatment in Western countries 
likely indicates under-prescription and undue postponement probably due to concerns about severe 
adverse events and the inconvenience of mandatory regular blood monitoring.
8 and 9
 By contrast, 
antipsychotic polypharmacy is commonly prescribed in TRS – despite the lack of evidence for its 
efficacy.
8 and 10
 The social and economic costs of untreated TRS are high,
11
 and duration of insufficiently 
treated or untreated psychosis is strongly associated with unfavorable long-term outcomes
12
. Therefore, 
identification of patients at high risk of TRS at the time of diagnosing schizophrenia would be of clinical 
benefit in minimizing the delay to clozapine treatment in TRS patients. The literature on predictors for 
TRS is sparse and the definition of TRS is not consistent between studies,
13
 and more research is needed 
to identify patient- and disease-related candidate predictors associated with TRS. 
A further motivation to identifying candidate predictors for TRS is to elucidate the etiology of TRS.  A 
critical question is whether TRS constitutes the severe end of a spectrum of schizophrenia, or whether 
TRS represents a distinct neurobiological entity that may respond to fundamentally different treatments in 
comparison with treatment-responsive schizophrenia. In the former case, the established risk factors for 
schizophrenia
14-17
 would be expected to apply even more strongly in TRS,
18
 whereas in the latter case, 
TRS would be expected to have a different profile of risk factors than schizophrenia per se. 
Our primary aim of this study was therefore to identify candidate predictors of a treatment-based proxy of 
TRS – including clozapine treatment and additionally another proxy for non-response to first-line 
treatment. To elucidate the underlying nature of TRS, our secondary aim was to investigate whether 
established risk factors for schizophrenia also predict treatment resistance.  
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Research in context 
Evidence before this study 
We searched PubMed for English-language publications from the date of inception to September 15, 2015 
using the terms “treatment resistant schizophrenia”, “treatment refractory schizophrenia”, 
“schizophrenia”, “clozapine”, “predictors”, and “risk factors”. Several studies were identified on risk 
factors for schizophrenia and clozapine treatment, while papers on predictors for treatment-resistant 
schizophrenia were few and differed in terms of both predictors and outcome definition.  
Added value of this study 
The current study supports and extends the knowledge on predictors for treatment-resistant schizophrenia 
by identifying several candidate predictors associated with treatment-resistant schizophrenia in a large 
population-based cohort. These candidate predictors obtained at baseline were: younger age at diagnosis, 
living in less urban areas, paranoid schizophrenia subtype, a history of psychiatric hospitalization, 
personality disorder, suicide attempts, and psychotropic drug use. Three different treatment-based proxy 
measures for treatment-resistant schizophrenia were examined and showed overall similar results. The 
most striking finding is that living in the capital area is associated with decreased rate of treatment 
resistance, despite urban living being a risk factor of schizophrenia in general. This suggests treatment-
resistant schizophrenia being an etiological distinct subtype of schizophrenia. 
Implications of all the available evidence 
The candidate predictors identified in this study could potentially be included in a clinical prediction 
model predicting who will require clozapine early after diagnosis of schizophrenia. Moreover, the 
findings might help to elucidate the underlying nature of treatment-resistant schizophrenia; i.e. whether it 
is only a more severe form of schizophrenia, or whether it also defines a distinct subtype of 
schizophrenia, as hypothesized in other pertinent research.  
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Methods 
Data sources  
The unique personal identification number assigned to all persons living in Denmark was used to link 
individual data across the national registration systems. We obtained information on sex, date of birth, 
and parents' personal identification numbers from the Danish Civil Registration System established in 
1968.
19
 We obtained information on admission dates and diagnoses (WHO International Classification of 
Diseases (ICD) version 8 and 10, see supplementary table A1) both from the Danish Psychiatric Central 
Research Register, and from the Danish National Patient Registry, containing information from all Danish 
hospitals.
20 and 21
 The Danish National Prescription Registry provided individual-level pharmacy-based 
information on all drug prescriptions since 1995.
22
 Socio-demographic information such as employment 
status, highest completed education level and marital status was obtained from the Danish Integrated 
Database for Labour Market and education registries via Statistics Denmark.
23
 We identified previous 
convictions for violent offences from the Central Criminal Register established in 1979.
24
 Complete 
information from all registries was available until December 31, 2010.  
Study cohort 
We performed a population-based cohort study, where the study cohort consisted of all patients born in 
Denmark after 1955, with a first recorded schizophrenia diagnosis (ICD-8 code 295.x9, excl. 295.79; 
ICD-10 code F20) at age 18 or older between January 1, 1996 and December 31, 2006. Patients were 
followed from the date of the first schizophrenia diagnosis until emigration, death, or December 31, 2010, 
whichever came first. Date of first diagnosis (baseline) was defined as the first contact (admission date if 
inpatient) leading to a schizophrenia diagnosis. We excluded patients dying during first admission and 
those redeeming clozapine prior to their first schizophrenia diagnosis (see figure 1).
25
 
Figure 1 approximately here 
Assessment of Treatment-Resistant Schizophrenia 
Our main TRS proxy was based only on patients’ antipsychotic prescription redemptions and psychiatric 
hospitalizations, and reflected previous and current Danish and international treatment guidelines
2 and 26-30
, 
and was defined as the earliest instance of either (i) first clozapine prescription redemption or (ii) meeting 
the eligibility criteria for clozapine, here defined as psychiatric hospital admission due to schizophrenia 
during antipsychotic treatment (as a proxy for insufficient treatment response) within 18 months after 
having had two periods of different antipsychotic monotherapy of at least six weeks duration. To account 
for antipsychotic treatment periods prior to first schizophrenia diagnosis we included prescription 
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redemptions during the year prior to the first schizophrenia diagnosis. In addition, we defined two 
alternative TRS proxy definitions, cf. figure 2. For further details see supplementary table A2. 
Figure 2 approximately here 
Assessment of candidate predictors of TRS 
We selected candidate predictors based on a literature search on risk factors for TRS or schizophrenia. 
We included identified factors which were available in the registers at first schizophrenia diagnosis. We 
defined two categories of candidate predictors available at baseline, i.e. at first schizophrenia diagnosis: 
patient-related and disease-related factors.  
Patient-related factors 
We included the following baseline factors (dichotomous variables unless otherwise specified, cf. table 
1): female sex, age (continuous), family history of schizophrenia (first-degree relatives), season of birth 
(born December-March), paternal age (continuous), early parental loss (before age 18), living alone, 
previous conviction for violent offence, primary (lowest) education level, employment status (4 levels), 
and urbanicity at first schizophrenia diagnosis (3 levels).  
Disease-related factors 
In addition we included the following baseline factors (dichotomous variables unless otherwise specified, 
cf. table 1): number of bed days at psychiatric hospital in year prior to first schizophrenia diagnosis (3 
levels), admission at psychiatric hospital, paranoid subtype, prior comorbid psychiatric diagnoses (table 1, 
defined by ICD-8 and ICD-10 codes
31
 cf. supplementary table A1), and psychotropic drugs redeemed in 
year prior to schizophrenia diagnosis; antipsychotics (ATC-code N05A, except N05AN01), 
antidepressants (ATC-code N06A), and benzodiazepines (ATC code N03AE, N05BA, N05CD, and 
N05CF).  
Statistical methods 
We performed multivariable Cox proportional hazards regression of the time to TRS to estimate the 
association between baseline candidate predictors and TRS. We chose Cox proportional hazards 
regression instead of a multivariable logistic regression model for prediction to account for varying time 
to TRS and to allow for censoring. We included a total of 23 candidate predictors in the model. Bipolar 
disorder, autism and attention deficit hyperactivity disorder were excluded due to low prevalence (table 
1). The proportional hazards assumption was assessed in diagnostic plots (not shown, available upon 
request). All statistical analyses were conducted in Stata 13 (StataCorp LP, College Station, TX, USA). 
All statistical tests were two-sided and deemed significant at a level of 5%. All hazard ratio (HR) 
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estimates are accompanied by 95% confidence intervals. For evaluation of the model we report 
McFadden estimated pseudo R
2
 for explained variability, and Harrell's C statistic as a measure for how 
well the model discriminated TRS from non-TRS.  
Sensitivity analyses 
The robustness of the results with respect to the outcome definition was explored by use of 1) a narrow 
TRS definition only including patients initiating clozapine, and 2) a broader TRS definition comprising 
patients who fulfilled the main TRS definition and additionally patients who were prescribed 
antipsychotic polypharmacy continuously for at least 90 days – a common management to treatment 
resistance in clinical practice in Denmark and internationally (figure 2).
32
 We repeated the main analysis 
censoring the data after two years follow-up to predict TRS occurring within the first two years only, to 
mimic current definitions of TRS and to limit the potential violations of the proportional hazards 
assumption due to long-term follow-up. We also repeated the main analysis restricted to new users of 
antipsychotics to evaluate the influence of prior antipsychotic use. Furthermore, we estimated HRs for 
each candidate predictor independently in models only including sex, age and year of diagnosis, to 
estimate independent associations with TRS and to check robustness of results. In addition, we conducted 
a Cox regression analysis where the baseline hazard was stratified on sex, age group (see table 1), and 
education level (primary versus higher). To evaluate the sensitivity due to missing values, we conducted 
analyses where missing values were replaced by the most extreme values (high vs. low). 
Results 
Participants 
We included 8624 schizophrenia patients fulfilling the inclusion criteria (figure 1). Of those, 7749 
(89·9%) were followed until the end of the study period, 763 (8·9%) died and 115 (1·3%) emigrated 
during follow-up. The total number of person-years was 77 888 with median follow-up of 9·1 years (IQR: 
6·3-11·9 years). 
Table 1 approximately here 
Baseline characteristics across groups meeting different criteria indicating TRS 
Of the study population 1137 (13·2%) redeemed at least one clozapine prescription (i), 990 (11·5%) were 
hospitalized after two periods of different antipsychotic monotherapy (ii), and 3773 (43·8%) are 
treated with polypharmacy for at least 90 days (iii). Overall, patients meeting criteria (i), (ii), or (iii) 
indicating TRS during follow-up had a different distribution of baseline characteristics from those not 
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meeting any of the three criteria indicating TRS, e.g. they were more likely to be female and younger at 
first schizophrenia diagnosis, living in less urban areas, having a history of psychiatric hospitalization, 
comorbid psychiatric diagnoses, and psychotropic medication. In particular, patients meeting criteria (i) 
and (ii) were very similar regarding most baseline characteristics (table 1).   
Candidate predictors of TRS 
In multivariable complete case analyses 1703 (21.2%) out of the total of 8044 fulfilled the main TRS 
proxy definition (criteria (i) or (ii), whichever came first). Baseline factors significantly associated with 
increased TRS were: younger age, living in less urban areas, higher education, psychiatric hospital 
admission at first schizophrenia diagnosis, having spent more than 30 bed days at psychiatric hospital in 
the previous year, paranoid subtype, comorbid personality disorder, suicide attempt, and psychotropic 
drug use (antipsychotics, antidepressants and benzodiazepines) (table 2).  
Table 2 approximately here 
Crude cumulative incidences of TRS are plotted stratified on sex, age at first schizophrenia diagnosis, 
hospital days in the previous year, and levels of urbanicity (figure 3).  
The variance explained by the full model was 2·7% (McFadden estimated pseudo R
2
) while the C-statistic 
was 0.70 indicating that the model discriminated sufficiently between TRS and non-TRS-patients. Both 
statistics though do not take censoring into account.    
Figure3 approximately here 
Sensitivity analyses 
In table 2, we showed - in addition to the results of the main TRS proxy – the results of similar analyses 
using 1) the more narrow TRS proxy of clozapine initiation only, and 2) the broader TRS proxy including 
90-day polypharmacy.  The alternative definitions resulted in similar estimates in terms of the size and 
direction of estimates (table 2). Moreover, long-term disability benefit, no substance abuse, and diagnosis 
of schizoaffective disorder, were marginally significantly associated with increased risk of subsequently 
taking clozapine. The broader TRS proxy including polypharmacy was associated with early parental 
loss, low education, long-term disability benefit, depression and substance abuse (table 2). Censoring 
follow-up to two years gave similar results, and further increased estimates for living in non-urban areas, 
psychiatric admissions, and psychotropic drug use, and higher education became insignificant 
(supplementary table A3). Restricting to new users of antipsychotics, the following factors remained 
significant: younger age, living in less urban areas, psychiatric hospitalization, paranoid subtype, 
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comorbid personality disorder, and suicide attempt. In addition, female sex was marginally significant 
(data not shown, available upon request). In models only including sex, age, and calendar year at first 
schizophrenia diagnosis and additional factors entered individually, education was not associated with 
TRS, and the following factors – in addition to those identified in the multivariable model – were 
significantly associated with increased TRS: female sex, previous conviction for violent offence, long-
term disability benefit, and prior psychiatric diagnoses listed (supplementary table A4). The analysis 
where the baseline hazard was stratified on sex, age group, and education level, resulted in 
similar/identical estimates as those shown in table 2. 
Effect of missingness 
Due to the low rates of missingness (family history (4·1%), paternal age (2·7%), education (2·7%), work 
status (0·1%)), we performed complete case analysis including 8044 (93·2%) of the 8624 patients in our 
original study population. Effect estimates resulting from analysis based on the original study population 
were largely unaffected by extreme value imputation of missing values and none changed direction. 
Discussion 
In this study we identified the following candidate predictors available at first schizophrenia diagnosis, 
which were significantly associated with increased rates of TRS: younger age, living in less urban areas, 
higher education, admitted at psychiatric hospital, paranoid subtype, and history of personality disorders, 
suicide attempts, and previous prescription of psychotropic drugs.  
Younger age at first schizophrenia diagnosis was consistently, regardless of TRS definition or model 
used, associated with increased rate of TRS in accordance with other research.
3,5,7, and 33
  
Disease-related factors such as more bed days in psychiatric hospital in the year prior to first 
schizophrenia diagnosis as well as hospital admission at first contact leading to a schizophrenia diagnosis 
were associated with increased TRS indicating that greater illness severity at schizophrenia onset is 
associated with a more complicated illness course. Prior diagnoses of personality disorder, suicide 
attempts, and paranoid schizophrenia subtype were all associated with increased TRS, which corroborates 
previous research.
33
  
Male sex, a well-established risk factor for schizophrenia in the general population,
17
 was not associated 
with increased TRS, with a (non-significant) opposite association. Moreover, urbanicity was found to be 
significantly associated with TRS – interestingly in opposite direction than for schizophrenia incidence in 
the general population.
34
 This finding of increased TRS in less urban areas may partly be explained by 
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different treatment practices across regions; supported by different rates of clozapine prescribing due to 
region or type of hospital.
5
 However, these findings are consistent with the possibility that, rather than 
representing a severe form of schizophrenia, the treatment-resistant subtype (i.e. TRS) may have a 
fundamentally different aetiology than the treatment-responsive subtype of schizophrenia. This fits with 
the emerging view that TRS may be a non-dopaminergic subtype of schizophrenia, and that TRS patients 
do not show the increased dopamine synthesis capacity seen in patients responsive to first-line 
antipsychotics.
35
  One possibility is that urban environments may confer increased risk for a 
‘dopaminergic’ form of psychosis, mediated by dopamine synthesis, which is responsive to treatment 
with dopamine-blocking drugs, while the treatment-resistant subtype shows no associations with 
urbanicity.
36
  
Strengths and limitations 
A major strength of this study is its size and comprehensiveness - it is a population-based longitudinal 
cohort study with up to 15 years follow-up of all adult and incident schizophrenia patients in Denmark, 
with very little missing data. The majority of previous studies on clozapine use or TRS has been cross-
sectional or was not analyzed longitudinally.
3,5,7, and 33
 We focused on adult onset schizophrenia, due to 
differing treatment guidelines and thus different definition of TRS for children. Factors related to 
clozapine treatment in patients with early onset of schizophrenia in Denmark have been investigated 
recently.
37
  
Several limitations are implicated by the register-based design. Regarding inclusion of candidate 
predictors or effect modifiers, several factors, such as smoking, body mass index, birth complications 
such as infection, and duration of untreated psychosis, were not available in the registers or were not 
suitable for this design only including factors obtainable at first diagnosis of schizophrenia. Regarding the 
TRS proxy definition we based it on clinical guidelines using data on prescriptions and psychiatric 
admissions obtainable from the registers. Ideally the definition would have included clinical scores as in 
the definition of Kane et al., including scores for positive and negative symptoms.
26
 However, these 
scores were not available in the registers. Almost all previous studies have, used proxy measures of TRS. 
In case of register-based studies, clozapine initiation has largely been used as a proxy.
3,5,8,13,18,33, and 38
 This 
is, however, not optimal since clozapine is under-prescribed and hence this will not capture all patients 
with TRS for whom clozapine could be a valid treatment option. 
 To minimize this limitation we considered not only clozapine treatment (i) as a proxy for treatment 
resistance, but also considered a treatment-based proxy criteria indicating insufficient treatment response 
to first-line treatment (ii).  
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We tested the robustness by applying the narrower and the broader TRS definitions and found that the 
results with regard to candidate predictors were quite robust across the applied definitions, although 
estimates did not consistently follow a gradient between the narrow category (clozapine only) through 
main and broad (including 90-day polypharmacy) categories. On the one hand, clozapine initiation might 
still be the strongest proxy for TRS, as it is prescribed based on clinical judgement. Assuming that 
clozapine is prescribed exclusively to patients with TRS, clozapine should have 100% precision for TRS. 
However, this TRS definition is too narrow to capture all patients with TRS due to the suspected underuse 
of clozapine in Western populations. Our main TRS definition therefore represents a reasonable trade-off 
between the two extremes (1. Clozapine initiation only – maximizing precision, and 2. TRS including 
polypharmacy – maximizing sensitivity), and results in 21.1% meeting the TRS criteria, in line with 
pertinent research
1
 and is further supported by the corroboration of some of the previously identified 
predictors of TRS, such as younger age, hospitalization, and psychiatric comorbidity.   
Though this approach closely reflects the treatment guidelines, we acknowledge that this pragmatic 
approach of considering patients having been through two antipsychotic monotherapy periods or 
polypharmacy as treatment resistant may include patients with side effects, poor tolerance or compliance
9
 
as well as a proportion of treatment-resistant patients. Information on prescribed dosage was not available 
and thus we might overestimate the number of adequate treatment periods of antipsychotic monotherapy. 
However, the very short trials on a probable low dosage were left out by restricting to monotherapy 
periods of at least two subsequent prescription redemptions and at least six weeks duration. Furthermore, 
information on medication during hospitalization was not available, which may potentially underestimate 
the number of adequate treatment periods of antipsychotic monotherapy and thus bias the TRS proxy 
definition. In addition, cost-free medication is sometimes given from the psychiatric hospital up to two 
years after discharge, which is not registered either. However the TRS proxy definition we have used in 
the current study appears to be the most appropriate approach for identifying TRS given the information 
available in registry data.  
Our results might also be biased since choice of medication does not only reflect the patients’ treatment 
resistance or severity of disease, but also the psychiatrists’ prescribing practices and/or patients’ and their 
relatives’ wishes or refusal of specific treatment. In particular switching from one antipsychotic to another 
during the early era of introduction of a number of atypical antipsychotics in the 1990s may reflect market 
penetration of the newer drugs rather than treatment resistance with regard to previously used drugs.  
Genetic data was not available for this study cohort. The growing interest of identifying genetic liability 
for schizophrenia and the increasing availability to collect larger genetic samples suggest that future 
12 
 
studies on prediction of TRS should strive to combine genetic data with the identified clinical and 
environmental predictors of TRS.  
Conclusion 
The current study used a treatment-based proxy for TRS to extend previous knowledge about predictors 
for TRS, suggesting that future prognostic studies for TRS should include disease-related factors such as 
history of other psychiatric diagnoses, suicide attempt, hospitalization and medication, as well as patient-
related factors such as sex, age, and urbanicity at first schizophrenia diagnosis. We hope that this study 
will contribute towards the development of a valid prediction models for identifying patients with TRS 
early after schizophrenia diagnosis, with potential applications in stratified medicine. Moreover, the 
findings of this study suggest that TRS may not be simply the severe end of a continuum of schizophrenia 
but may represent a distinct subtype. 
13 
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Figure and Table legends and footnotes 
 
Figure 1: Flow chart illustrating the inclusion and exclusion criteria for the study population, n=8624. 
Figure 2: Criteria indicating TRS, and TRS proxy definitions derived from registry data. 
a) Antipsychotic treatment periods are defined from prescription data and a more detail description can be 
found in supplementary table A2. 
Table 1: Baseline characteristics for schizophrenia patients meeting different criteria indicating TRS. 
Table 2: Hazard rate ratio (HR) and 95% confidence interval (CI) for TRS (main proxy definition, and 
two alternative proxy definitions) estimated for each candidate predictor in a multivariable model 
including all listed baseline factors as well as calendar year at first schizophrenia diagnosis, n=8044. 
Figure 3: Crude cumulative incidence curves of TRS based on a competing risks regression with death 
as a competing event. Cumulative incidences are shown in strata of sex, age at first schizophrenia 
diagnosis, number of hospital days in previous year, and levels of urbanicity. 
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Abstract 
BACKGROUND Identification of patients at high risk of treatment-resistant schizophrenia (TRS) at the 
time of diagnosing schizophrenia would be of great clinical benefit when considering clozapine treatment 
earlier for patients unlikely to respond to non-clozapine antipsychotics. Knowledge about TRS predictors 
is limited. Using a treatment-based proxy for TRS, we aimed to identify candidate predictors of TRS at 
first hospital contact with a schizophrenia diagnosis. 
METHODS Using Danish National registry data we conducted a population-based cohort study among 
all adult patients with incident schizophrenia between January 1, 1996 and December 31, 2006 followed 
until 31 December, 2010. As main TRS proxy definition we considered the earliest instance of either (i) 
clozapine initiation or (ii) hospitalization for schizophrenia after having had two periods of different 
antipsychotic monotherapy. We performed multivariable Cox proportional hazards regression analysis.  
FINDINGS Of 8624 patients with schizophrenia, 21·1% fulfilled the TRS proxy definition during 
follow-up (median 9·1 years, IQR: 6·3-11·9). Younger age, living in a less urban area, higher education, 
previous psychiatric hospitalization, paranoid subtype, comorbid personality disorder, psychotropic drug 
use, and previous suicide attempt, were all significantly associated with an increased rate of TRS. 
INTERPRETATION The current study identifies several candidate predictors which could potentially 
be included in future prediction models for TRS. Notably, established risk factors for schizophrenia did 
not predict TRS, suggesting that TRS may be a distinct subtype of schizophrenia, and not merely a more 
severe form of schizophrenia.  
FUNDING The research leading to these results has received funding from the European Community's 
Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 279227. The funding agency 
has had no impact in any aspect of data review, interpretation and manuscript writing. 
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Introduction 
Treatment-resistant schizophrenia (TRS) is clinically defined as non-response to at least two adequate 
trials of antipsychotic medication, and is estimated to affect approximately 30% of all patients with 
schizophrenia.
1 and ;2
. 
Clozapine is the only treatment for TRS with a firm evidence base as reflected by official treatment 
guidelines
2
. Compared with the estimated prevalence of TRS of 30%, the prevalence of clozapine 
prescription varies from 2-3% in parts of the US
3
, to nearly 60% in China
3 and ;4
 with around 10% in most 
Western European countries including Denmark
5
. This is partly a consequence of variations between 
national treatment guidelines.
6 and ;7
. Moreover, the low rate of clozapine treatment in Western countries 
likely indicates under-prescription and undue postponement probably due to concerns about severe 
adverse events and the inconvenience of mandatory regular blood monitoring.
8 and ;9
. By contrast, 
antipsychotic polypharmacy is commonly prescribed in TRS – despite the lack of evidence for its 
efficacy.
8 and ;10
. The social and economic costs of untreated TRS are high,
11
, and duration of insufficiently 
treated or untreated psychosis is strongly associated with unfavorable long-term outcomes
12
. Therefore, 
identification of patients at high risk of TRS at the time of diagnosing schizophrenia would be of clinical 
benefit in minimizing the delay to clozapine treatment in TRS patients. The literature on predictors for 
TRS is sparse and the definition of TRS is not consistent between studies,
13
, and more research is needed 
to identify patient- and disease-related candidate predictors associated with TRS. 
A further motivation to identifying candidate predictors for TRS is to elucidate the etiology of TRS.  A 
critical question is whether TRS constitutes the severe end of a spectrum of schizophrenia, or whether 
TRS represents a distinct neurobiological entity that may respond to fundamentally different treatments in 
comparison with treatment-responsive schizophrenia. In the former case, the established risk factors for 
schizophrenia
14-17
 would be expected to apply even more strongly in TRS,
18
, whereas in the latter case, 
TRS would be expected to have a different profile of risk factors than schizophrenia per se
1
. 
Our primary aim of this study was therefore to identify candidate predictors of a treatment-based proxy of 
TRS – including clozapine treatment and additionally another proxy for non-response to first-line 
treatment. To elucidate the underlying nature of TRS, our secondary aim was to investigate whether 
established risk factors for schizophrenia also predict treatment resistance.  
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Research in context 
Evidence before this study 
We searched PubMed, without date restrictions, for English-language publications from the date of 
inception to September 15, 2015 using the terms “treatment resistant schizophrenia”, “treatment 
refractory schizophrenia”, “schizophrenia”, “clozapine”, “predictors”, and “risk factors”. Several studies 
were identified on risk factors for schizophrenia and clozapine treatment, while papers on predictors for 
treatment-resistant schizophrenia were few and differed in terms of both predictors and outcome 
definition.  
Added value of this study 
The current study supports and extends the knowledge on predictors for treatment-resistant schizophrenia 
by identifying several candidate predictors associated with treatment-resistant schizophrenia in a large 
population-based cohort. These candidate predictors obtained at baseline were: younger age at diagnosis, 
living in less urban areas, paranoid schizophrenia subtype, a history of psychiatric hospitalization, 
personality disorder, suicide attempts, and psychotropic drug use. Three different treatment-based proxy 
measures for treatment-resistant schizophrenia were examined and showed overall similar results. The 
most striking finding is that living in the capital area is associated with decreased rate of treatment 
resistance, despite urban living being a risk factor of schizophrenia in general. This suggests treatment-
resistant schizophrenia being an etiological distinct subtype of schizophrenia. 
Implications of all the available evidence 
The candidate predictors identified in this study could potentially be included in a clinical prediction 
model predicting who will require clozapine early after diagnosis of schizophrenia. Moreover, the 
findings might help to elucidate the underlying nature of treatment-resistant schizophrenia; i.e. whether it 
is only a more severe form of schizophrenia, or whether it also defines a distinct subtype of 
schizophrenia, as hypothesized in other pertinent research.  
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Methods 
Data sources  
The unique personal identification number assigned to all persons living in Denmark was used to link 
individual data across the national registration systems. We obtained information on sex, date of birth, 
and parents' personal identification numbers from the Danish Civil Registration System established in 
1968. 
19
. We obtained information on admission dates and diagnoses (WHO International Classification 
of Diseases (ICD) version 8 and 10, see supplementary tableTABLE A1) both from the Danish 
Psychiatric Central Research Register
20
, and from the Danish National Patient Registry, containing 
information from all Danish hospitals.
20 and 21
. The Danish National Prescription Registry provided 
individual-level pharmacy-based information on all drug prescriptions since 1995.
22
. Socio-demographic 
information such as employment status, highest completed education level and marital status was 
obtained from the Danish Integrated Database for Labour Market and education registries via Statistics 
Denmark.
23
. We identified previous convictions for violent offences from the Central Criminal Register 
established in 1979.
24
. Complete information from all registries was available until December 31, 2010.  
Study cohort 
We performed a population-based cohort study, where the study cohort consisted of all patients born in 
Denmark after 1955, with a first recorded schizophrenia diagnosis (ICD-8 code 295.x9, excl. 295.79; 
ICD-10 code F20) at age 18 or older between January 1, 1996 and December 31, 2006. Patients were 
followed from the date of the first schizophrenia diagnosis until emigration, death, or December 31, 2010, 
whichever came first. Date of first diagnosis (baseline) was defined as the first contact (admission date if 
inpatient) leading to a schizophrenia diagnosis. We excluded patients dying during first admission and 
those redeeming clozapine prior to their first schizophrenia diagnosis (see figureFIGURE 1).
25
 
Figure 1 approximately here 
Assessment of Treatment-Resistant Schizophrenia 
Our main TRS proxy was based only on patients’ antipsychotic prescription redemptions and psychiatric 
hospitalizations, and reflected previous and current Danish and international treatment guidelines
2 and ;26-30
, 
and was defined as the earliest instance of either (i) first clozapine prescription redemption or (ii) meeting 
the eligibility criteria for clozapine, here defined as psychiatric hospital admission due to schizophrenia 
during antipsychotic treatment (as a proxy for insufficient treatment response) within 18 months after 
having had two periods of different antipsychotic monotherapy of at least six weeks duration. To account 
for antipsychotic treatment periods prior to first schizophrenia diagnosis we included prescription 
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redemptions during the year prior to the first schizophrenia diagnosis. In addition, we defined two 
alternative TRS proxy definitions, cf. figureFIGURE 2. For further details see supplementary 
tableTABLE A2. 
Figure 2 approximately here 
Assessment of candidate predictors of TRS 
We selected candidate predictors based on a literature search on risk factors for TRS or schizophrenia. 
We included identified factors which were available in the registers at first schizophrenia diagnosis. We 
defined two categories of candidate predictors available at baseline, i.e. at first schizophrenia diagnosis: 
patient-related and disease-related factors.  
Patient-related factors 
We included the following baseline factors (dichotomous variables unless otherwise specified, cf. 
tableTABLE 1): female sex, age (continuous), family history of schizophrenia (first-degree relatives), 
season of birth (born December-March), paternal age (continuous), early parental loss (before age 18), 
living alone, previous conviction for violent offence, primary (lowest) education level, employment status 
(4 levels), and urbanicity at first schizophrenia diagnosis (3 levels).  
Disease-related factors 
In addition we included the following baseline factors (dichotomous variables unless otherwise specified, 
cf. tableTABLE 1): number of bed days at psychiatric hospital in year prior to first schizophrenia 
diagnosis (3 levels), admission at psychiatric hospital, paranoid subtype, prior comorbid psychiatric 
diagnoses (table 1, defined by ICD-8 and ICD-10 codes
31
 cf. supplementary tableTABLE A1), and 
psychotropic drugs redeemed in year prior to schizophrenia diagnosis; antipsychotics (ATC-code N05A, 
except N05AN01), antidepressants (ATC-code N06A), and benzodiazepines (ATC code N03AE, N05BA, 
N05CD, and N05CF).  
Statistical methods 
We performed multivariable Cox proportional hazards regression of the time to TRS to estimate the 
association between baseline candidate predictors and TRS. We chose Cox proportional hazards 
regression instead of a multivariable logistic regression model for prediction to account for varying time 
to TRS and to allow for censoring. We included a total of 23 candidate predictors in the model. Bipolar 
disorder, autism and attention deficit hyperactivity disorder were excluded due to low prevalence 
(tableTABLE 1). The proportional hazards assumption was assessed in diagnostic plots (not shown, 
available upon request). All statistical analyses were conducted in Stata 13 (StataCorp LP, College 
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Station, TX, USA). All statistical tests were two-sided and deemed significant at a level of 5%. All hazard 
ratio (HR) estimates are accompanied by 95% confidence intervals. For evaluation of the model we report 
McFadden estimated pseudo R
2
 for explained variability, and Harrell's C statistic as a measure for how 
well the model discriminated TRS from non-TRS.  
Sensitivity analyses 
The robustness of the results with respect to the outcome definition was explored by use of 1) a narrow 
TRS definition only including patients initiating clozapine, and 2) a broader TRS definition comprising 
patients who fulfilled the main TRS definition and additionally patients who were prescribed 
antipsychotic polypharmacy continuously for at least 90 days – a common management to treatment 
resistance in clinical practice in Denmark and internationally
32
 (figure 2FIGURE 2).
32
 We repeated the 
main analysis censoring the data after two years follow-up to predict TRS occurring within the first two 
years only, to mimic current definitions of TRS and to limit the potential violations of the proportional 
hazards assumption due to long-term follow-up. We also repeated the main analysis restricted to new 
users of antipsychotics to evaluate the influence of prior antipsychotic use. Furthermore, we estimated 
HRs for each candidate predictor independently in models only including sex, age and year of diagnosis, 
to estimate independent associations with TRS and to check robustness of results. In addition, we 
conducted a Cox regression analysis where the baseline hazard was stratified on sex, age group (see 
tTable 1), and education level (primary versus higher). To evaluate the sensitivity due to missing values, 
we conducted analyses where missing values were replaced by the most extreme values (high vs. low). 
Results 
Participants 
We included 8624 schizophrenia patients fulfilling the inclusion criteria (figureFIGURE 1). Of those, 
7749 (89·9%) were followed until the end of the study period, 763 (8·9%) died and 115 (1·3%) emigrated 
during follow-up. The total number of person-years was 77 888 with median follow-up of 9·1 years (IQR: 
6·3-11·9 years). 
Table 1 approximately here 
Baseline characteristics across groups meeting different criteria indicating TRS 
Of the study population 1137 (13·2%) redeemed at least one clozapine prescription (i), 990 (11·5%) were 
hospitalized after two periods of different antipsychotic monotherapy (ii), and 3773 (43·8%) are 
treated with polypharmacy for at least 90 days (iii). Overall, patients meeting criteria (i), (ii), or (iii) 
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indicating TRS during follow-up had a different distribution of baseline characteristics from those not 
meeting any of the three criteria indicating TRS, e.g. they were more likely to be female and younger at 
first schizophrenia diagnosis, living in less urban areas, having a history of psychiatric hospitalization, 
comorbid psychiatric diagnoses, and psychotropic medication. In particular, patients meeting criteria (i) 
and (ii) were very similar regarding most baseline characteristics (tableTABLE 1).   
Candidate predictors of TRS 
In multivariable complete case analyses 1703 (21.2%) out of the total of 8044 fulfilled the main TRS 
proxy definition (criteria (i) or (ii), whichever came first). Baseline factors significantly associated with 
increased TRS were: younger age, living in less urban areas, higher education, psychiatric hospital 
admission at first schizophrenia diagnosis, having spent more than 30 bed days at psychiatric hospital in 
the previous year, paranoid subtype, comorbid personality disorder, suicide attempt, and psychotropic 
drug use (antipsychotics, antidepressants and benzodiazepines) (tableTABLE 2).  
Table 2 approximately here 
Crude cumulative incidences of TRS are plotted stratified on sex, age at first schizophrenia diagnosis, 
hospital days in the previous year, and levels of urbanicity (figure 3FIGURE 3).  
The variance explained by the full model was 2·7% (McFadden estimated pseudo R
2
) while the C-statistic 
was 0.70 indicating that the model discriminated sufficiently between TRS and non-TRS-patients. Both 
statistics though do not take censoring into account.    
Figure3 approximately here 
Sensitivity analyses 
In tableTABLE 2, we showed - in addition to the results of the main TRS proxy – the results of similar 
analyses using 1) the more narrow TRS proxy of clozapine initiation only, and 2) the broader TRS proxy 
including 90-day polypharmacy.  The alternative definitions resulted in similar estimates in terms of the 
size and direction of estimates (tableTABLE 2). Moreover, long-term disability benefit prior to 
schizophrenia diagnosis, no substance abuse, and prior diagnosis of schizoaffective disorder, were 
marginally significantly associated with increased risk of subsequently taking clozapine. The broader 
TRS proxy including polypharmacy was associated with early parental loss, low education, long-term 
disability benefit, depression and substance abuse (tableTABLE 2). Censoring follow-up to two years 
gave similar results, and further increased estimates for living in non-urban areas, psychiatric admissions, 
and psychotropic drug uses, and higher education became insignificant (supplementary tableTABLE A3). 
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Restricting to new users of antipsychotics, the following factors remained significant: younger age, living 
in less urban areas, psychiatric hospitalization, paranoid subtype, comorbid personality disorder, and 
suicide attempt. In addition, female sex was marginally significant (data not shown, available upon 
request). In models only including sex, age, and calendar year at first schizophrenia diagnosis and 
additional factors entered individually, education was not associated with TRS, and the following factors 
– in addition to those identified in the multivariable model – were significantly associated with increased 
TRS: female sex, previous conviction for violent offence, long-term disability benefit, and prior 
psychiatric diagnoses listed (supplementary tableTABLE A4). The analysis where the baseline hazard 
was stratified on sex, age group, and education level, resulted in similar/identical estimates as those 
shown in table 2. 
Effect of missingness 
Due to the low rates of missingness (family history (4·1%), paternal age (2·7%), education (2·7%), work 
status (0·1%)), we performed complete case analysis including 8044 (93·2%) of the 8624 patients in our 
original study population. Effect estimates resulting from analysis based on the original study population 
were largely unaffected by extreme value imputation of missing values and none changed direction. 
Discussion 
In this study we identified the following candidate predictors available at first schizophrenia diagnosis, 
which were significantly associated with increased rates of TRS: younger age, living in less urban areas, 
higher education, admitted at psychiatric hospital, paranoid subtype, and history of personality disorders, 
suicide attempts, and previous prescription of psychotropic drugs.  
Younger age at first schizophrenia diagnosis was consistently, regardless of TRS definition or model 
used, associated with increased rate ofrisk for TRS in accordance with other research.
3,;5,;7, and ;33
.  
Disease-related factors such as more bed days in psychiatric hospital in the year prior to first 
schizophrenia diagnosis as well as hospital admission at first contact leading to a schizophrenia diagnosis 
were associated with increased TRS indicating that greater illness severity at schizophrenia onset is 
associated with a more complicated illness course. Prior diagnoses of personality disorder, suicide 
attempts, and paranoid schizophrenia subtype were all associated with increased TRS, which corroborates 
previous research.
33
.  
Male sex, a well-established risk factor for schizophrenia in the general population,
17
, was not associated 
with increased TRS, with a (non-significant) opposite association. Moreover, urbanicity was found to be 
10 
 
significantly associated with TRS – interestingly in opposite direction than for schizophrenia incidence in 
the general population.
34
. This finding of increased TRS in less urban areas may partly be explained by 
different treatment practices across regions; supported by different rates of clozapine prescribing due to 
region or type of hospital.
5
. However, these findings are consistent with the possibility that, rather than 
representing a severe form of schizophrenia, the treatment- resistant subtype (i.e. TRS) may have a 
fundamentally different aetiology than the treatment- responsive subtype of schizophrenia. This fits with 
the emerging view that TRS may be a non-dopaminergic subtype of schizophrenia, and that TRS patients 
do not show the increased dopamine synthesis capacity seen in patients responsive to first-line 
antipsychotics.
35
.  One possibility is that urban environments may confer increased risk for a 
‘dopaminergic’ form of psychosis, mediated by dopamine synthesis, which is responsive to treatment 
with dopamine-blocking drugs, while the treatment-resistant subtype shows no associations with 
urbanicity.
36
.  
Strengths and limitations 
A major strength of this study is its size and comprehensiveness - it is a population-based longitudinal 
cohort study with up to 15 years follow-up of all adult and incident schizophrenia patients in Denmark, 
with very little missing data. The majority of previous studies on clozapine use or TRS has been cross-
sectional or was not analyzed longitudinally.
3,;5,;7, and ;33
. We focused on adult onset schizophrenia, due to 
differing treatment guidelines and thus different definition of TRS for children. Factors related to 
clozapine treatment in patients with early onset of schizophrenia in Denmark have been investigated 
recently.
37
.  
Several limitations are implicated by the register-based design. Regarding inclusion of candidate 
predictors or effect modifiers, several factors, such as smoking, body mass index, birth complications 
such as infection, and duration of untreated psychosis, were not available in the registers or were not 
suitable for this design only including factors obtainable at first diagnosis of schizophrenia. Regarding the 
TRS proxy definition we based it on clinical guidelines using data on prescriptions and psychiatric 
admissions obtainable from the registers. Ideally the definition would have included clinical scores as in 
the definition of Kane et al.
26
, including scores for positive and negative symptoms.
26
 However, these 
scores were not available in the registers. Almost all previous studies have, used proxy measures of TRS. 
In case of register-based studies, clozapine initiation has largely been used as a proxy.
3,;5,;8,;13,;18,;33, and ;38
. 
This is, however, not optimal since clozapine is under-prescribed and hence this will not capture all 
patients with TRS for whom clozapine could be a valid treatment option. 
11 
 
 To minimize this limitation we considered not only clozapine treatment (i) as a proxy for treatment 
resistance, but also considered a treatment-based proxy criteria indicating insufficient treatment response 
to first-line treatment (ii).  
We tested the robustness by applying the narrower and the broader TRS definitions and found that the 
results with regard to candidate predictors were quite robust across the applied definitions, although 
estimates did not consistently follow a gradient between the narrow category (clozapine only) through 
main and broad (including 90-day polypharmacy) categories. On the one hand, clozapine initiation might 
still be the strongest proxy for TRS, as it is prescribed based on clinical judgement. Assuming that 
clozapine is prescribed exclusively to patients with TRS, clozapine should have 100% precision for TRS. 
However, this TRS definition is too narrow to capture all patients with TRS due to the suspected underuse 
of clozapine in Western populations. Our main TRS definition therefore represents a reasonable trade-off 
between the two extremes (1. Clozapine initiation only – maximizing precision, and 2. TRS including 
polypharmacy – maximizing sensitivity), and results in 21.1% meeting the TRS criteria, in line with 
pertinent research
1
 and is further supported by the corroboration of some of the previously identified 
predictors of TRS, such as younger age, hospitalization, and psychiatric comorbidity.   
Though this approach closely reflects the treatment guidelines, we acknowledge that this pragmatic 
approach of considering patients having been through two antipsychotic monotherapy periods or 
polypharmacy as treatment resistant may include patients with side effects, poor tolerance or compliance
9
 
as well as a proportion of treatment- resistant patients. Information on prescribed dosage was not 
available and thus we might overestimate the number of adequate treatment periods of antipsychotic 
monotherapy. However, the very short trials on a probable low dosage were left out by restricting to 
monotherapy periods of at least two subsequent prescription redemptions and at least six6 weeks duration. 
Furthermore, information on medication during hospitalization was not available, which may potentially 
underestimate the number of adequate treatment periods of antipsychotic monotherapy and thus bias the 
TRS proxy definition. In addition, cost-free medication is sometimes given from the psychiatric hospital 
up to two years after discharge, which is not registered either. However the TRS proxy definition we have 
used in the current study appears to be the most appropriate approach for identifying TRS given the 
information available in registry data.  
Our results might also be biased since choice of medication does not only reflect the patients’ treatment 
resistance or severity of disease, but also the psychiatrists’ prescribing practices and/or patients’ and their 
relatives’ wishes or refusal of specific treatment. In particular switching from one antipsychotic to another 
during the early era of introduction of a number of atypical antipsychotics in the 1990s may reflect market 
penetration of the newer drugs rather than treatment resistance with regard to previously used drugs.  
12 
 
Genetic data was not available for this study cohort. The growing interest of identifying genetic liability 
for schizophrenia, and the increasing availability to collect larger genetic samples, suggests that future 
studies on prediction of TRS should strive to combine genetic data with the identified clinical and 
environmental predictors of TRS.  
Conclusion 
The current study used a treatment-based proxy for TRS to extend previous knowledge about predictors 
for TRS, suggesting that future prognostic studies for TRS should include disease-related factors such as 
history of other psychiatric diagnoses, suicide attempt, hospitalization and medication, as well as patient-
related factors such as sex, age, and urbanicity at first schizophrenia diagnosis. We hope that this study 
will contribute towards the development of a valid prediction models for identifying patients with TRS 
early after schizophrenia diagnosis, with potential applications in stratified medicine. Moreover, the 
findings of this study suggest that TRS may not be simply the severe end of a continuum of schizophrenia 
but may represent a distinct subtype. 
13 
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Figure and Table legends and footnotes 
 
Figure 1: Flow chart illustrating the inclusion and exclusion criteria for the study population, n=8624. 
Figure 2: Criteria indicating TRS, and TRS proxy definitions derived from registry data. 
a) Antipsychotic treatment periods are defined from prescription data and a more detail description can be 
found in supplementary tTable A2. 
Table 1: Baseline characteristics for schizophrenia patients meeting different criteria indicating TRS. 
Table 2: Hazard rate ratio (HR) and 95% confidence interval (CI) for TRS (main proxy definition, and 
two alternative proxy definitions) estimated for each candidate predictor in a multivariable model 
including all listed baseline factors as well as calendar year at first schizophrenia diagnosis, n=8044. 
Figure 3: Crude cumulative incidence curves of TRS based on a competing risks regression with death 
as a competing eventrisk. Cumulative incidences are shown in strata of sex, age at first schizophrenia 
diagnosis, number of hospital days in previous year, and levels of urbanicity. 
 
Table 1: Baseline characteristics for schizophrenia patients meeting d ifferent criteria indicating 
TRS. 
 
 Criteria   
 (i) 
Clozapine 
initiation 
(ii) 
Eligible for 
clozapine 
(iii) 
90-day 
polypharmacy 
Others not 
meeting criteria 
(i), (ii), or (iii)  
All diagnosed 
with 
schizophrenia 
 n % n % n % n % n % 
Total, n (%) 1137 13·2% 990 11·5% 3773 43·8% 4470 51·8% 8624 100% 
Patient-related factors 
Patient-related factors 
          
Female sex vs. male sex 478 42·0% 458 46·3% 1564 41·5% 1537 34·4% 3248 37·7% 
Age at first SZ diagnosis, median (IQR) 26·4 (22·1-32·4) 27·3 (22·5-34·5) 28·2 (23·1-35·2) 29·7 (23·7-36·5) 28·9 (23·4-35·8) 
Age           
    18-24 years 479 42·1% 383 38·7% 1330 35·3% 1373 30·7% 2844 33·0% 
    25-34 years 457 40·2% 370 37·4% 1462 38·7% 1770 39·6% 3379 39·2% 
    35-52 years 201 17·7% 237 23·9% 981 26·0% 1327 29·7% 2401 27·8% 
Family history of SZ vs. not (N=8269) 70 6·4% 68 7·2% 265 7·3% 314 7·3% 615 7·4% 
Season of birth (Born Dec-March) 366 32·2% 336 33·9% 1235 32·7% 1502 34·0% 2883 33·4% 
Paternal age, median (IQR) (N=8388) 29·0 (25·2-33·1) 28·7 (25·1-33·1) 28·7 (25-33·4) 29·2 (25·4-33·9) 29·0 (25·2-33·7) 
Early parental loss 80 7·0% 77 7·8% 318 8·4% 311 7·0% 655 7·6% 
Living alone vs. couple (N=8558) 570 50·2% 512 51·8% 2007 53·3% 2447 55·5% 465 54·3% 
Violent offence 138 12·1% 124 12·5% 445 11·8% 579 13·0% 1067 12·4% 
Primary education vs. higher (N=8389) 687 61·9% 614 63·4% 2374 64·7% 2487 57·2% 5071 60·4% 
Employment status (N=8620)           
    In work 345 30·3% 278 28·1% 1043 27·6% 1444 32·3% 2613 30·3% 
    Outside working force    561 49·3% 495 50·0% 1803 47·8% 2072 46·4% 4054 47·0% 
    Unemployed 84 7·4% 69 7·0% 285 7·6% 424 9·5% 742 8·6% 
    Long-term disability benefit 147 12·9% 148 14·9% 642 17·0% 526 11·8% 1211 14·0% 
Urbanicity (Place of living at time of first 
SZ diagnosis )  
          
    Capital area (capital and suburb  
    to the capital)  
308 27·1% 254 25·7% 1073 28·4% 1913 42·8% 3103 36·0% 
    Provincial area (>10000 inhabitants)  556 48·9% 484 48·9% 1717 45·5% 1763 39·4% 3666 42·5% 
    Rural area  273 24·0% 252 25·5% 983 26·1% 794 17·8% 1855 21·5% 
Disease-related factors           
Bed days at psychiatric hospitals in year 
prior to first SZ diagnosis 
          
    0 days 574 50·5% 495 50·0% 2129 56·4% 3155 70·6% 5499 63·8% 
    1-30 days 200 17·6% 202 20·4% 699 18·5% 683 15·3% 1450 16·8% 
    >30 days 363 31·9% 293 29·6% 945 25·0% 632 14·1% 1675 19·4% 
In-patient at  first SZ diagnosis 747 65·7% 634 64·0% 2089 55·4% 1788 40·0% 4125 47·8% 
Paranoid subtype at  first SZ diagnosis 644 56·6% 559 56·5% 206 54·6% 2307 51·6% 459 53·2% 
Prior psychiatric diagnoses           
SZ affective disorder 67 5·9% 53 5·4% 190 5·0% 124 2·8% 336 3·9% 
Other SZ spectrum disorders 547 48·1% 488 49·3% 1791 47·5% 1796 40·2% 3771 43·7% 
Bipolar disorder 43 3·8% 48 4·8% 159 4·2% 161 3·6% 341 4·0% 
Depression 259 22·8% 258 26·1% 859 22·8% 666 14·9% 1596 18·5% 
Autism 19 1·7% 12 1·2% 52 1·4% 51 1·1% 107 1·2% 
Attention Deficit Hyperactivity Disorder 4 0·4% 5 0·5% 27 0·7% 33 0·7% 60 0·7% 
Substance abuse (including alcohol, 
cannabis, and smoking use disorders) 
365 32·1% 378 38·2% 1312 34·8% 1221 27·3% 2650 30·7% 
Personality disorder 434 38·2% 413 41·7% 1355 35·9% 1055 23·6% 2525 29·3% 
Suicide attempt 304 26·7% 301 30·4% 981 26·0% 675 15·1% 1727 20·0% 
Drugs redeemed in previous year           
Antipsychotics 644 56·6% 612 61·8% 2155 57·1% 1555 34·8% 3901 45·2% 
Antidepressants 449 39·5% 421 42·5% 153 40·6% 1196 26·8% 2846 33·0% 
Benzodiazepines 508 44·7% 432 43·6% 1648 43·7% 1197 26·8% 2984 34·6% 
Table
Table 1: Hazard rate ratio (HR) and 95% confidence interval (CI) for TRS (main proxy definition, 
and two alternative proxy definitions) estimated for each candidate predictor in a multivariable 
model including all listed baseline factors as well as calendar year at first schizophrenia diagnosis, 
n=8044. 
 
 
 Clozapine only TRS main 
 
TRS including 
polypharmacy 
Number of events 1071 1703 3878 
Total person-time at risk (years) 65 657 61 421 47 395 
Rate per 100 person-years 1·62 2·77 8·19 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Patient-related factors       
Female sex versus male sex 1·00 (0·87-1·14) 1·07 (0·96-1·19) 1·04 (0·97-1·12) 
Age at  first SZ diagnosis 0·94 (0·93-0·95) 0·96 (0·95-0·97) 0·98 (0·97-0·98) 
Family history of SZ versus not (n=8269) 0·92 (0·72-1·18) 1·00 (0·83-1·21) 1·03 (0·91-1·17) 
Season of birth (Born Dec-March) 0·96 (0·84-1·09) 1·01 (0·91-1·11) 0·97 (0·90-1·03) 
Paternal age (n=8388) 1·00 (0·99-1·01) 1·00 (0·99-1·01) 1·00 (0·99-1·00) 
Early parental loss 0·88 (0·69-1·12) 0·97 (0·81-1·16) 1·16 (1·03-1·30) 
Living alone versus couple 0·99 (0·88-1·12) 1·00 (0·91-1·11) 1·01 (0·95-1·08) 
Violent offence 1·12 (0·91-1·37) 1·04 (0·89-1·23) 0·92 (0·82-1·02) 
Primary education level versus higher (n=8389) 0·83 (0·72-0·95) 0·88 (0·79-0·98) 1·09 (1·01-1·17) 
Employment status (n=8620)       
    In work 1  1  1  
    Outside working force    0·95 (0·83-1·10) 1·01 (0·90-1·13) 1·06 (0·98-1·14) 
    Unemployed 0·86 (0·67-1·09) 0·95 (0·79-1·15) 0·94 (0·83-1·07) 
    Long-term disability benefit 1·23 (0·98-1·55) 1·14 (0·95-1·36) 1·32 (1·17-1·47) 
Urbanicity ( Place of living at time of first 
schizophrenia diagnosis) 
      
    Capital area (capital and suburb to the capital)  1  1  1  
    Provincial area (>10·000 inhabitants)  1·40 (1·21-1·63) 1·38 (1·23-1·56) 1·38 (1·27-1·49) 
    Rural area  1·40 (1·18-1·67) 1·44 (1·25-1·65) 1·61 (1·47-1·76) 
Disease-related factors       
Bed days (psyc) in year prior to first 
schizophrenia diagnosis 
      
    0 days 1  1  1  
    1-30 days 1·07 (0·90-1·28) 1·11 (0·96-1·27) 1·04 (0·95-1·14) 
    >30 days 1·62 (1·38-1·91) 1·54 (1·35-1·75) 1·30 (1·19-1·42) 
In-patient at  first schizophrenia diagnosis 2·06 (1·81-2·34) 2·07 (1·87-2·29) 1·63 (1·53-1·74) 
Paranoid subtype at first schizophrenia diagnosis 1·31 (1·16-1·48) 1·24 (1·13-1·37) 1·15 (1·08-1·23) 
Prior psychiatric diagnoses       
SZ affective disorder 1·28 (0·99-1·65) 1·18 (0·95-1·45) 1·14 (0·98-1·31) 
Other SZ spectrum disorders 1·05 (0·92-1·20) 1·05 (0·94-1·16) 1·02 (0·95-1·09) 
Depression  1·07 (0·91-1·26) 1·11 (0·97-1·26) 1·10 (1·01-1·19) 
Substance abuse 0·88 (0·76-1·02) 0·99 (0·88-1·11) 1·10 (1·02-1·19) 
Personality disorder 1·23 (1·07-1·42) 1·24 (1·11-1·39) 1·15 (1·07-1·24) 
Suicide attempt 1·19 (1·02-1·39) 1·21 (1·07-1·39) 1·21 (1·11-1·31) 
Drugs redeemed in year    
prior to first SZ diagnosis 
      
Antipsychotics 1·33 (1·16-1·54) 1·51 (1·35-1·69) 1·60 (1·48-1·72) 
Antidepressants 1·13 (0·98-1·30) 1·15 (1·03-1·29) 1·22 (1·13-1·31) 
Benzodiazepines 
 
1·33 (1·15-1·53) 1·22 (1·10-1·37) 1·34 (1·25-1·44) 
 
Table
Born in Denmark after January 1, 1955, and diagnosed with 
schizophrenia for the first time between January 1, 1996 and 
December 31, 2006.  
N = 9332 
First schizophrenia diagnosis at 18 years or older. 
N = 8769 
First clozapine redeemed after first schizophrenia diagnosis. 
N = 8624 
Alive at first psychiatric discharge. 
N = 8754 
First schizophrenia diagnosis before age 18. 
N = 563 
Dead during first in-patient schizophrenia contact. 
N = 15 
Clozapine redeemed prior to first schizophrenia diagnosis. 
N = 130 
Figure
 CRITERIA INDICATING TRS 
(i) (ii) (iii) 
”Clozapine initiation” ”Eligible for clozapine” ”90-day polypharmacy” 
The date on which the first 
clozapine prescription was 
redeemed at the pharmacy after 
first schizophrenia diagnosis. 
Psychiatric hospitalization with 
a schizophrenia diagnosis within 
18 months after having had two 
periodsa of at least 6 weeks 
duration with different non-
clozapine antipsychotic 
monotherapies. 
 
At least 90-days overlap of 
periodsa of  two or more 
different antipsychotics. 
 
TRS PROXY DEFINITIONS 
”Clozapine only” ”TRS main” ”TRS including polypharmacy” 
(i) (i) or (ii) (i) or (ii) or (iii) 
Clozapine initiation Clozapine initiation or eligible 
for clozapine. 
 
Clozapine initiation,  
eligible for clozapine, or  
90-day polypharmacy. 
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